GT Biopharma Long-Term Debt 2011-2026 | GTBP

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:

Term exceeds 12 months
Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
Repaid through regular payments (interest and/or principal) over several years

Why long-term debt is needed:

Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:

Mortgage loans for property purchases
Corporate bonds issued by a company to raise capital
Project financing — long-term loans for building or expanding production facilities
Leasing obligations for equipment or transport

Annual Long-Term Debt GT Biopharma

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	64 K	-	-	-	-	-	-	714 K	634 K	97 K	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
714 K	64 K	377 K

Quarterly Long-Term Debt GT Biopharma

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	31 K	64 K	92 K	120 K	147 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	400 K	528 K	553 K	714 K	714 K	714 K	714 K	634 K	634 K	634 K	634 K	97 K	97 K	97 K	97 K	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
714 K	31 K	386 K

Long-Term Debt of other stocks in the Biotechnology industry

Issuer	Long-Term Debt	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	273 M	-	2.43 %	$ 254 M	Germany
Alterity Therapeutics Limited ATHE	59.9 K	$ 5.15	15.21 %	$ 12.4 B	Australia
Allakos ALLK	38.2 M	-	-	$ 28.6 M	USA
AlloVir ALVR	1.13 M	-	4.14 %	$ 49.1 M	USA
I-Mab IMAB	68.2 M	-	-	$ 866 M	China
Applied Molecular Transport AMTI	49 K	-	-	$ 10.1 M	USA
Alexion Pharmaceuticals, Inc. ALXN	2.42 B	-	-	$ 40.3 B	USA
Applied Therapeutics APLT	38 K	-	-	$ 8.42 M	USA
Aptinyx APTX	22.1 M	-	-39.0 %	$ 4.57 M	USA
Genfit SA GNFT	173 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	1.83 M	-	-13.47 %	$ 169 M	France
Advaxis ADXS	8.14 M	-	-9.65 %	$ 45.9 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	278 K	-	-1.52 %	$ 24.7 M	USA
Akouos AKUS	28.3 M	-	0.23 %	$ 488 M	USA
Midatech Pharma plc MTP	4.76 M	-	-18.52 %	$ 27.3 M	Britain
Aligos Therapeutics ALGS	122 K	$ 6.51	-2.54 %	$ 64.4 M	USA
Amphastar Pharmaceuticals AMPH	620 M	$ 22.92	0.17 %	$ 1.07 B	USA
Avenue Therapeutics ATXI	2.03 M	-	-52.27 %	$ 4.45 M	USA
BioNTech SE BNTX	231 M	$ 105.19	2.21 %	$ 27.2 B	Germany
Aravive ARAV	1.88 M	-	-13.39 %	$ 1.45 M	USA
Институт стволовых клеток человека ISKJ	175 M	-	-	-	Russia
Aeterna Zentaris AEZS	31 K	-	5.93 %	$ 314 M	Canada
AstraZeneca PLC AZN	17.5 B	-	-	$ 96.9 B	Britain
AgeX Therapeutics AGE	2.95 M	-	-10.17 %	$ 12.2 K	USA
Brainstorm Cell Therapeutics BCLI	171 K	-	-2.5 %	$ 5.88 M	USA
Aeglea BioTherapeutics AGLE	4 M	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	48.2 M	$ 1.43	1.78 %	$ 368 M	USA
BioDelivery Sciences International BDSI	78.5 M	-	-4.8 %	$ 255 M	USA
Ayala Pharmaceuticals AYLA	1.33 M	-	-	$ 7.46 M	Israel
Applied Genetic Technologies Corporation AGTC	9.12 M	-	-	$ 26.5 M	USA
BeiGene, Ltd. BGNE	962 M	-	0.49 %	$ 251 B	Cayman-islands
Aquestive Therapeutics AQST	45 M	$ 4.24	-1.85 %	$ 453 M	USA
Arcutis Biotherapeutics ARQT	108 M	$ 24.47	-0.24 %	$ 3.11 B	USA
AIkido Pharma AIKI	2.29 M	-	1.93 %	$ 17.4 M	USA
Autolus Therapeutics plc AUTL	66.8 M	$ 1.58	-1.25 %	$ 420 M	Britain
Aptose Biosciences APTO	193 K	-	-45.71 %	$ 1.2 M	Canada
BioXcel Therapeutics BTAI	84.7 M	$ 1.2	4.35 %	$ 14.6 M	USA
AVROBIO AVRO	188 K	-	1083.1 %	$ 745 M	USA
Cabaletta Bio CABA	2.88 M	$ 3.31	-3.92 %	$ 333 M	USA
bluebird bio BLUE	37.7 M	-	-	$ 546 M	USA
Fennec Pharmaceuticals FENC	30.9 M	$ 6.73	-0.88 %	$ 192 M	USA
Akero Therapeutics AKRO	529 K	-	-	$ 3.67 B	USA
CureVac N.V. CVAC	25.4 M	-	-	$ 867 M	Germany
CymaBay Therapeutics CBAY	467 K	-	-	$ 3.45 B	USA
Cidara Therapeutics CDTX	310 K	-	-	$ 1.41 B	USA
ChromaDex Corporation CDXC	1.82 M	-	-0.88 %	$ 598 M	USA
Allena Pharmaceuticals ALNA	210 K	-	3.16 %	$ 1.9 M	USA
ContraFect Corporation CFRX	2.21 M	-	-5.16 %	$ 5.39 M	USA